14 Oct 2024
ZERO Biotech, a leading provider of nuclear medicine services in Hong Kong, is committed to raising awareness about the benefits of nuclear medicine and expanding its services to cater to the growing demand for cancer treatment.
"We believe that nuclear medicine has the potential to revolutionize cancer treatment, and we are dedicated to making it more accessible to patients in Hong Kong and beyond," said Clement Tam, CEO of ZERO Biotech.
The company has been at the forefront of nuclear medicine in Hong Kong, providing diagnosis and treatment services for cancer patients. With its state-of-the-art facilities and team of experienced professionals, ZERO Biotech is well-positioned to cater to the specific needs of Asian patients.
ZERO Biotech is currently working on several projects, including the development of a new nuclear medicine based on Lutetium 177, which targets to complete clinical trials within three years. The company has also partnered with a renowned research institute in mainland China to introduce a new molecular drug that has the potential to diagnose and treat various types of cancer.
"We are excited about the prospects of nuclear medicine and are committed to working with medical professionals, researchers, and investors to bring this technology to the frontier of cancer treatment," said Clement.